Glioblastoma is the most common and aggressive primary brain tumor in the adult population and leads to considerable morbidity and mortality. It has a dismal prognosis with average survival of 15-18 months, and the current standard-of-care treatment paradigm includes maximal surgical resection and postoperative concurrent chemoradiotherapy and maintenance chemotherapy, with consideration of Tumor…
AbstractPurpose:. Immune checkpoint inhibitors (ICI) have been a potential treatment option for patients with cervical cancer in several clinical studies. We investigated the safety and…
Registration for the OncoAlert ASCO 5k to be held on June 1st, 2024 at 7am local time and will start at the Hyatt Regency McCormick…
Registration for the OncoAlert ASCO 5k to be held on June 1st, 2024 at 7am local time and will start at the Hyatt Regency McCormick…
The OncoAlert Newsletter is now out for June 23-29, 2023
The OncoAlert Newsletter is now out for June 23-29, 2023
PURPOSE Datopotamab deruxtecan (Dato-DXd) is an antibody-drug conjugate consisting of a humanized antitrophoblast cell-surface antigen 2 (TROP2) monoclonal antibody linked to a potent, exatecan-derived topoisomerase…
Objective To describe the clinicopathological characteristics and survival outcomes of ovarian neuroendocrine neoplasms from a curated registry. Methods This is a retrospective cross-sectional study of…
Registration for the OncoAlert ASCO 5k to be held on June 1st, 2024 at 7am local time and will start at the Hyatt Regency McCormick…
EGFR is often found to be constitutively activated in human cancer. Dobersberger et al. develop an engineering strategy for the generation of binding domains specifically recognizing…
DAY 1 (GU Oncology)February 5, 2024 Start 6pm CET 12 noon EST6pm-6:20 (CET)12 noon-12:20 (EST)Gilberto Morgan (20 min) FDA Approvals in Oncology, OncoAlert …
